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Introduction: Home mechanical ventilation (HMV) in the Netherlands is normally initiated in
hospital, but this is expensive and often a burden for the patient. In this randomised controlled
study we investigated whether initiation of HMV at home in patients with chronic respiratory
failure is non-inferior to an in hospital based setting.
Methods: Seventy-seven patients were included, of which 38 patients started HMV at home. All
patients were diagnosed with chronic respiratory failure due to a neuromuscular or thoracic
cage disease. Primary outcome was the arterial carbon dioxide (PaCO2) while quality of life
and costs were secondary outcomes. Telemonitoring was used in the home group to provide
therapeutic information, for example; transcutaneous carbon dioxide, oxygen saturation and
ventilator information, to the caregivers. Follow-up was six months.
Results: PaCO2, improved by 0.72 (SE  0.16) kPa in the hospital group and by 0.91 (0.20) in
the home group, both improvements being significant and the latter clearly not inferior.
There were also significant improvements in quality of life in both groups, again not being
inferior with home treatment.edical Center Groningen, Department of Pulmonology and Tuberculosis, Department of Home Me-




1388 A. Hazenberg et al.Conclusion: This study is the first to show that initiation of HMV at home in a selective group of
patients with chronic respiratory failure is as effective for gas exchange and quality of life as
hospital initiation. In addition we found that it is safe, technically feasible and that more than
V 3000 per patient can be saved compared to our standard care.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Home mechanical ventilation (HMV) in the Netherlands
routinely starts in a clinical setting as recommended in the
national guideline and typically requires several days, up to
a week of hospitalisation [1]. Nocturnal arterial blood gas
analysis while on HMV complete the initiation period and are
performed at the intensive care. It is intuitive that the costs
of starting HMV in a hospital setting are substantial higher
than at home which is the topic of our study. In addition
being admitted to a hospital for patients is not only an
emotional burden, it also increases the risk of developing a
nosocomial infection [2]. Patients on HMV are mostly
severely disabled and it is often, perhaps paradoxically,
challenging to provide the same high level of individually
tailored care in hospital as compared to home. These are all
very important reasons to investigate whether the initiation
of HMV cannot be carried out in the home setting.
A problem of the initiation of HMV at home so far has
been the lack of professional supervision in the home
environment and night time observation during sleep. A
probable solution for this problem is the use of tele-
monitoring to transmit digital data and provide clinical
health care outside the hospital [3,4]. The data in patients
with HMV comprises of ventilator settings and physiological
data, for example carbon dioxide and oxygen saturation
levels. It has been shown that telemonitoring can be cost-
effective and in certain settings is able to transfer the
burden of care from health-care professionals to family and
home-care personnel [5]. In the latter study patients with
chronic obstructive pulmonary disease (COPD) on oxygen or
HMV were monitored by tele-assistance which reduced both
hospitalisations and urgent calls compared to the control
group that received standard care.
As we do not know if the initiation of HMV at home is
effective, technically feasible and cost-effective we set up
a randomised controlled trail.
Our hypothesis was that initiation of HMV at home, by
using telemonitoring, in a selective group of patients with
chronic respiratory failure due to neuromuscular disease
(NMD) or thoracic cage disorder is not inferior compared to
initiation in a hospital. The primary outcome measure was
the arterial carbon dioxide (PaCO2) while quality of life and
costs were secondary outcome measurements.
Methods
Subjects
The study design was single-centre, prospective, rando-
mised and controlled. Patients diagnosed with chronicrespiratory failure due to a NMD or thoracic cage disorder
being referred to our outpatient clinic were screened for
participation in this study. Chronic respiratory failure was
defined as daytime PaCO2 >6.0 kPa (>45 mmHg) [6,7] with
complaints of respiratory failure (pulmonary infections,
headache, daytime sleepiness, concentration problems) as
stated in our national guideline. [1] Patients with orthop-
nea due to diaphragm paralysis and daytime normocapnia
were also included. Patients younger than 18 years, those
who needed invasive ventilation and the ones that lived in a
nursing home were excluded. We excluded patients with
strictly COPD as HMV is not a standard therapy in the
Netherlands in those patients. Patients not naı̈ve to a mask,
for example failure after CPAP therapy and patients with an
acute episode of respiratory failure were also excluded.
The study was approved by the Medical Ethics Committee of
the University of Groningen, University Medical Center of
Groningen and written informed consent was obtained from
all patients. The trial was registered with the Netherlands
Trial Registry (NTR number 1476).
Randomisation and intervention
Patients started HMV at home or in the hospital in random
order. Stratification was done for patients with Amyo-
trophic Lateral Sclerosis (ALS) to prevent a possible imbal-
ance between the two groups. Randomisation was done by
an independent statistician using a stratified block ran-
domisation with a block size of 6.
Measurements
Daytime arterial blood gasses were taken from the radial
artery, in sitting position and without oxygen supplemen-
tation or HMV at baseline and 6 months after the initiation
of HMV at the outpatient clinic.
Patients completed the following questionnaires: Severe
Respiratory Insufficiency (SRI) [8], Maugeri Respiratory
Failure (MRF-28) [9], Hospital Anxiety and Depression Scale
(HADS) [10] and the Short-Form Health Survey (SF-36) [11].
The SRI contains seven domains; respiratory complaints,
physical functioning, attendant symptoms and sleep, social
relationships, anxiety, psychological well-being and social
functioning. The MRF contains three domains; daily activ-
ity, cognitive function and invalidity. The HADS contains the
anxiety and depression domain. The SF-36 contains eight
domains; physical functioning; role physical; bodily pain;
general health; vitality; social functioning; role emotional
and mental health.
Forced vital capacity was measured by spirometry
(Masterscreen Viasys, Bodystat Ltd, Isle of Man, UK.).
Figure 1 Setup of the telemonitoring equipment at home.
Ventilator Elisée 150, humidifier Fisher and Paykel HC 150,
transcutaneous monitor Tosca, laptop with mobile
connection.
Initiation of home mechanical ventilation at home 1389Carbon dioxide and oxygen saturation were assessed
through the skin of the earlobe, by Tosca (Linde Medical
Sensors AG. Basel. Switzerland) [12].
A standard procedure describing the technical setup of
HMV was used both at home and in the hospital. All patients
started with the Elisée 150 ventilator (ResMed Paris, Fr.).
The choice of the interface could be a nasal, full-face,
mouth or total-face mask. The ventilator in the pressure
mode was set up at the start with an inspiratory pressure of
10 cm H2O; a positive end expiratory pressure (PEEP) of
4 cm H2O; a target volume of 8e10 ml/kg and a ventilatory
rate close to the patients breathing frequency. The set up
in the volume mode started at a volume of 8e10 ml/kg; a
PEEP of 4 cm H2O and a ventilatory rate close to the pa-
tients breathing frequency. The standard procedure
described which actions should be taken to change the
ventilator settings during the initiation of HMV. For
example, if the patient needed more air, the inspiratory
pressure was increased and if the patient snored during the
PEEP was increased. During the initiation of HMV adjust-
ments to the ventilator and or interface were done to
improve the blood gasses and the patients comfort resulting
in a good night sleep.
Initiation of home mechanical ventilation in the
hospital
Standard care during the initiation of HMV in our hospital
entails admission on a regular respiratory ward with spe-
cifically trained personnel. The first day of admission the
patient started HMV with the intention to get used to the
interface and to adjust to the ventilator settings. Patients
were instructed to use the ventilator as long as possible
during the first night. They were allowed to stop the HMV
during the night and if applicable start again early in the
morning for another session. Every day the necessary ac-
tions including, adjusting ventilator settings or interface
were performed. The patient had to sleep at least 6 h with
the ventilator, before he was transferred to the intensive
care unit (ICU) to assess arterial blood gasses, through a
radialis catheter, during the night while using the HMV. The
latter being the standard routine in the Netherlands. If
normalisation of carbon dioxide and oxygen saturation
levels while on the ventilator were reached, the patient
was discharged. The ventilator was installed at home by a
nurse of the department of HMV. After two months the
patient was admitted again to the ICU for nocturnal arterial
blood gas assessment while on HMV. The patient had to
bring their own home ventilator to the hospital.
Follow-up was six months after starting HMV at the
outpatient clinic to assess an arterial blood gas analysis and
lung function.
Initiation of home mechanical ventilation at home
Initiation of HMV at home started during the first visit at the
patient’s home by the nurse practitioner (NP). The venti-
lator, humidifier and transcutaneous monitor were installed
in the patient’s bedroom (Fig. 1). This installation also
included the laptop, mobile connection and the software
program that was used to send digital data of the devices tothe hospital. The first time the patient was ventilated the
NP was present. After instruction was given to the patient
and if necessary to the caregivers they practiced the HMV
themselves at daytime. If in the first night, when trying to
sleep with the HMV, the patient woke up and could not
continue because of discomfort they were allowed to stop.
The following days and nights they tried to extend the
number of hours on HMV. Patients were instructed to call
the department of HMV 24/7 if problems occurred. If
sputum mobilisation was a problem patients were instruc-
ted to use air stacking and one ventilator mode was
adjusted for mouthpiece ventilation. Every day the venti-
lator information (e.g. volume, frequency, pressure levels,
hours ventilator was used) was sent to the hospital and
evaluated by the NP. The NP informed the patient about the
results over the telephone and if necessary the ventilator
settings were adjusted by the patient or the care giver.
Changing the ventilator settings while on the phone with
the NP is part of the instruction at the start of HMV. The
transcutaneous monitor was attached the moment the pa-
tient could sleep for six hours while being on HMV. The next
day the measurements of the transcutaneous monitor and
the ventilator were evaluated, by using telemonitoring.
When the results showed a normalisation of the carbon
dioxide and oxygen saturation, the initiation period was
ended during a house call by the NP. The transcutaneous
monitor and the telemonitoring equipment were returned
to the hospital. Two months after the initiation of HMV,
transcutaneous monitoring at home was performed again.
Follow-up was six months after starting HMV at the
outpatient clinic to assess an arterial blood gas analysis and
lung function.Telemonitoring
Every morning during the initiation period of HMV at home,
the data of the ventilator and if applicable of the trans-
cutaneous monitor was sent to the hospital. The data
comprised of ventilator settings, respiratory rate and
1390 A. Hazenberg et al.carbon dioxide and oxygen saturation levels. The NP
received the anonymised digital data by email and phoned
with the patient to evaluate the results. A laptop was used
to transfer the information collected by the ventilator and
transcutaneous monitor to the hospital. A software program
especially developed for this study started the data
collection of the ventilator and transcutaneous monitor
automatically.Cost analysis
Units of health care consumption that were registered
included admission days to the general ward and ICU, time
spent by the nurse practitioner (including house calls) and
travelling expenses. Volumes of health care consumption
were multiplied with their cost prices according to the
Dutch guideline for cost studies [13]. The 2012 price level
was used. Costs are displayed in Euro’s (V). The time ho-
rizon of the cost study was equal to that of the clinical
study and was 6 months. Mean total costs per patient were
calculated for both interventions separately. Confidence
intervals (95%CI’s) were computed based on bootstrap re-
sampling with 5000 replications of the trial dataset.Figure 2 Flow diagram. Home group: initiation of home mecha
mechanical ventilation in the hospital. COPD: chronic obstructive
CPAP: continuous positive airway pressure.Statistical analysis
The primary outcome analysis was PaCO2 which was based
on intention-to-treat (ITT) analysis. The power analysis was
based on a non-inferiority test of the difference of two
means. With an alpha of 0.05, a beta of 0.2, a standard
deviation off 0.71 and a maximum difference in PaCO2 of
0.5 kPa, it was necessary to have two groups off 26 pa-
tients. A paired-sample T-test was performed to determine
the difference within groups and an independent-sample T-
test for the difference (D) between groups. The level of
statistical significance was set at p < 0.05. Statistical an-
alyses were performed using IBM SPSS Statistics 20 (IBM,
New York, USA).Results
380 patients started non-invasive HMV in the University
Medical Center of Groningen (UMCG) during the inclusion
period which lasted from October 2008 till October 2012
(Fig. 2). Of the 84 patients that were eligible, 77 were
randomised (Table 1). Eight in each group withdrew during
follow-up. Additional information in the Supplementarynical ventilation at home. Hospital group: initiation of home
pulmonary disease. BIPAP: bi-level positive airway pressure.






Age in years 59.9  12.6 56.9  13.9
Neuromuscular disease 33 35
Thoracic cage disorder 5 4
Body mass Index kg-m2 27  6.3 27  6.8
Blood gas analysis room air
Ph 7.40  0.3 7.40  0.3
PaCO2 kPa 6.6  0.9 6.6  1.1
PaO2 kPa 10.0  1.7 9.5  1.3
SaO2 % 95  2.9 94  2.7
HCO3 mmol/l 30.2  3.8 30.4  3.8
VC % predicted 50.3  20.9 51.6  18.1
FEV1/VC 79.3  12.2 81.2  15.7
Pack years 14.3  11.2 29.5  17.8
Current smokers 2 3
Wheelchair-bound 16 12
Data are presented as n or mean  SD.
kPa: kilopascal. Ph: acidity level. PaCO2: partial pressure of
arterial carbon dioxide. PaO2: partial pressure of arterial oxy-
gen. SaO2: arterial oxygen saturation. HCO3: bicarbonate. VC:
vital capacity. FEV1: forced expiratory volume in one second.
Initiation of home mechanical ventilation at home 1391files Table 1. The largest group in this study was diagnosed
with ALS (4 with bulbar involvement); 10 patients in the
hospital group had diaphragm paralysis and 4 in the home
group. Two patients crossed from intervention, one in the
hospital group and the other in the home group. They
remained in the initial group for all ITT analysis. Both
analysis per protocol and ITT did not resulted in different
outcomes. We also evaluated the variety in diagnoses and
did not find a significant difference between both groups.
One patient with limb girdle dystrophy in the home
group and 1 patient with ALS in the hospital group used HMV
when their blood gasses were assessed during 6 months
follow-up due to the progression of their illness.
In the home group 5 patients died versus 2 in the hospital
group. In no case was this due to technical problems in the
home settings. Patients died varying from one week up to
almost 6 months after starting HMV, all experiencing a non-
acute progression of their disease (ALS).
Twenty-five patients in the home group and 28 patients
in the hospital group were not able to perform physical
activities regarding the maintenance of HMV. The care
givers were instructed during the initiation of HMV at home
while this was done after being discharged in the hospital
group.Blood gas analysis and ventilator settings
Daytime PaCO2, the primary endpoint, improved by 0.72
(SE  0.16) kPa in the hospital group and by 0.91 (0.20) in
the home group being not significantly different between
both groups (Table 2). Nocturnal transcutaneous registra-
tion showed an improvement in both groups, both after
initiation and after two months (Table 3).Both groups started with the same ventilator settings
and only minor adjustments were needed during the follow-
up of six months (Fig. 3). Three patients were ventilated in
the volume mode and the other 74 in the pressure
controlled mode. In the home group a mean of 11 (1.86)
days was needed to initiate HMV and in the hospital group 8
(0.54) days. Follow-up after 6 months showed that pa-
tients at home slept a mean of 10.0 (0.83) hours with HMV
and the hospital group 8.5 (0.67) hours.
Health related quality of life
The hospital and home group improved significantly on two
of seven SRI subscales. The improvements in SRI score form
baseline to six months follow-up were not inferior (or
significantly better) in the home group compared to the
hospital group.
The MRF-28 showed a significant improvement in the
hospital group on the total score but not in the home group,
however not being significantly different between both
groups. The other MRF-28 domain scores were both within
and between groups not significantly different. The HADS
showed no significant changes both within and between
groups. The SF-36 showed a significant improvement in the
domain vitality in both groups. The other SF-36 domains
showed no significant changes between groups (Table 4).
Costs
Due to the travel time in the home group the total invested
time by NP per patient was 91 min longer compared to the
hospital group. In contrast the contact time per patient in
the hospital group was higher (Fig. 4). The NP visited the
patient the first day and if necessary the following days.
This was not specified in the standard procedure and
resulted in a mean of 3 visited during the initiation period
of HMV.
Total mean costs per patient amounted to V 726 per
patient in the home group and to V 3913 in the hospital
group (difference e V 3187; 95% CI -V3643 toeV 2694).
Mean costs in the hospital group amounted to V 3618 for
admission to the ICU and the ward, V198 for contact with
the NP and V 97 for travelling expenses. Mean costs in the
home group included V 192 of travelling expenses, V 266 of
house calls and consult by telephone by the nurse practi-
tioner, and V 268 for hospital admissions. As the other
costs; masks, ventilator, disposables supply and trans-
cutaneous measurement were similar in both groups this
was not accounted for.
Telemonitoring
Since the procedure of initiation of HMV at a distance, i.e.
at home, is new and the software program for tele-
monitoring was specifically developed for this study, pa-
tients were instructed to contact the 24/7 call service of
the HMV department if necessary. The use of tele-
monitoring did not result in problems or calls during the
night. Adjusting ventilator settings, while interacting with
the patient or caregivers, went well after good instructions
during the initiation process.
Table 2 Changes in daytime arterial blood gasses and lung function pre home mechanical ventilation to 6 months after the
start.
Home group (n Z 30) Hospital group (n Z 31) Between groups
Baseline Follow-up P-Valuea Baseline Follow-up P-Valuea P-valueb
Ph 7.40  0.3 7.40  0.3 0.261 7.40  0.3 7.40  0.3 0.913 0.423
PaCO2 (kPa) 6.6  0.9 5.7  0.8 0.000 6.6  1.1 5.9  0.8 0.000 0.631
PaO2 (kPa) 10.0  1.7 11.3  2.2 0.002 9.5  1.3 10.3  1.7 0.015 0.579
SaO2 % 95  2.9 96  1.9 0.020 94  2.7 95  3.6 0.348 0.598
HCO3 (mmol/l) 30.2  3.8 26.6  3.1 0.000 30.4  3.8 26.9  2.5 0.000 0.996
aBE 4.9  2.6 2.6  1.7 0.000 4.8  2.8 2.2  1.8 0.000 0.283
FVC (% pred) 51.6  22.8 53.4  21.8 0.528 52.4  18.5 49.8  19.0 0.301 0.428
Data are presented as n or mean  SD.
kPa: kilopascal. Ph: acidity level. PaCO2: partial pressure of arterial carbon dioxide. PaO2: partial pressure of arterial oxygen. SaO2:
arterial oxygen saturation. HCO3: bicarbonate. VC: vital capacity. Follow-up: six months after the initiation of home mechanical
ventilation.
Bold: p < 0.05 significant change.
a P-value refers to paired t test analysis form starting ventilatory support to six months follow-up within each group.
b P-value for difference in change D from baseline between groups.
Table 3 Changes in nocturnal transcutaneous carbon dioxide and oxygen saturation.









tcpCO2 (kPa) 7.6  1.0 6.5  0.9 5.8  0.7 7.4  1.3 6.4  0.8 5.7  0.7
Maximal tcpCO2 (kPa) 8.7  1.4 7.3  0.9 6.7  0.8 8.4  1.8 7.3  0.9 6.6  0.2
Oxygen saturation (%) 91.3  5.1 95.2  1.8 96.2  1.8 91.8  4.9 95.7  1.7 95.9  1.7
Lowest oxygen saturation (%) 74.6  15.2 86.6  8.2 84.7  12.8 74.4  14.6 84.1  9.2 85.7  7.2
Data are presented mean  SD.
tcpCO2: transcutaneous carbon dioxide. kPa: kilo pascal.
1392 A. Hazenberg et al.Technical problems did occur initially in 11 out of the 38
patients who started HMV at home. In 3 patients the wireless
connectionwas not successful because of insufficientmobile
connection facilities as our part of the country is not veryFigure 3 Ventilator settings from initiation to six months
follow-up. Insp. pres: inspiratory pressure in cm H2O above
peep. PEEP: positive end expiratory pressure in cm H2O. Fre-
quency: ventilator frequency. Initiation: after the initiation of
home mechanical ventilation. Follow-up: 6 months follow-up
after starting home mechanical ventilation.densely populated. Another reason was that patients with
ALS sometimes live in an iron surfaced mobile unit, with
bedroom and washroom facilities on the ground floor. The
iron surface disturbs the mobile connection. In these 11
cases the evaluation of the patients’ condition was done on
individual clinical parameters; sleeping timewithHMV, sleep
quality and improvement of quality of life during the day.Discussion
This is the first study showing that initiation of home me-
chanical ventilation at home, in a selective group of pa-
tients with a stable respiratory problem, resulted in
improvements in blood gasses and quality of life being not
inferior to in hospital initiation. In addition it showed that
the start of HMV at home, by using telemonitoring, was
safe, feasible and cheaper.
Publications concerning the initiation of HMV outside the
hospital by using telemonitoring are scarce. One study
showed a reduction in health care utilization in patients
with ALS after using home telemonitoring [14]. Initiation of
HMV was done in the hospital and the follow-up was carried
out at home by using telemonitoring. They used a fixed
telephone line with limited speed of data transferral. In our
study we started HMV at home and we used a mobile
connection allowing us to move the equipment from one
Table 4 Changes in health related quality of life measurements pre home mechanical ventilation to 6 months after the start.
Home group (n Z 30) Hospital group (n Z 35) Between groups
Baseline Follow-up P-valuea Baseline Follow-up P-valuea P-valueb
SRI
RC 47.6  19.5 55.5  17.3 0.023 48.6  18.5 51.9  17.6 0.114 0.462
PF 28.8  21.4 31.9  21.5 0.994 36.6  20.5 32.9  20.5 0.452 0.585
AS 55.1  18.6 69.6  18.0 0.000 48.5  19.1 60.9  16.7 0.000 0.904
SR 68.5  12.3 69.5  12.7 0.723 71.2  12.8 66.9  11.8 0.204 0.247
AX 55.0  21.1 57.8  24.2 0.474 54.7  16.8 60.9  16.7 0.159 0.628
WB 57.1  19.8 57.3  24.0 1.000 60.3  15.7 59.7  18.3 0.946 0.963
SF 52.7  19.1 51.9  22.3 0.298 57.2  17.5 55.1  18.5 0.733 0.603
SS 52.1  14.4 56.2  16.4 0.153 53.9  12.3 55.4  12.0 0.248 0.762
MRF-28
Daily activities 58.1  27.9 59.7  27.6 0.741 60.3  29.0 53.2  28.1 0.182 0.706
Cognition 35.0  32.6 29.4  33.5 0.372 37.1  35.4 30.0  34.7 0.143 0.836
Invalidity 53.3  38.5 61.3  37.1 0.241 57.1  34.7 57.1  34.7 1.000 0.333
Total score 52.1  21.1 49.2  23.1 0.466 58.2  19.7 45.2  20.9 0.000 0.038
HADS
Depression 6.6  4.2 6.0  4.5 0.319 7.1  3.5 6.4  4.2 0.139 0.985
Anxiety 6.4  4.7 6.1  4.9 0.193 6.8  3.8 6.1  3.4 0.195 0.589
Total score 13.0  8.0 12.1  8.7 0.660 13.9  6.8 12.5  7.1 0.175 0.760
SF-36
PF 13.2  18.5 15.6  19.1 0.832 17.1  22.1 18.8  23.6 0.784 0.983
RP 15.7  33.6 25.0  35.9 0.565 13.1  24.4 25.7  35.0 0.013 0.337
BP 66.8  30.7 66.1  29.6 0.853 64.2  29.2 60.5  24.5 0.612 0.863
GH 30.7  24.8 35.2  27.2 0.805 30.2  17.3 36.0  19.6 0.058 0.205
VT 39.0  21.4 52.1  22.6 0.004 36.5  18.9 45.2  18.9 0.004 0.967
SF 52.6  32.9 58.7  32.8 0.881 55.0  21.7 60.3  27.3 0.338 0.602
RE 54.3  52.8 57.4  47.0 0.508 48.2  46.3 57.1  45.4 0.209 0.864
MH 66.3  21.8 72.2  22.0 0.040 64.7  17.5 69.7  17.0 0.055 0.993
Data are presented as n or mean  SD.
SRI: Severe Respiratory Insufficiency (0 Z worst possible health 100 Z best possible health) respiratory complaints (RC), physical
functioning (PF), attendant symptoms and sleep (AS), social relationship (SR), anxiety (AX), psychological well-being (WB), social
functioning (SF), summary score (SS).
MRF-28: Maugeri Respiratory Failure (0 Z worst possible health 100 Z best possible health).
HADS: Hospital Anxiety Depression Scale (total score: 0 Z best possible health 42 is worst possible health; separate score 0e21).
SF-36: Short-Form Health Status Survey (0 Z worst possible health 100 Z best possible health) PF Z physical functioning, RP Z role
physical; BP Z bodily pain; GH Z general health; VT Z vitality; SF Z social functioning; RE Z role emotional; MH Z mental health.
Bold: p < 0.05 significant change.
a P-value refers to paired t test analysis form starting ventilatory support to six months follow-up within each group.
b P-value for difference in change D from baseline between groups.
Initiation of home mechanical ventilation at home 1393patient to the other without technical workout delays.
Another study showed that telemonitoring can be more
effective in patients who are more compliant to the ther-
apy [15]. The installation of the telemonitoring system at
the patient’s home in our study was self-supporting mean-
ing that the data transfer was not dependent on the tech-
nical skills or actions to be taken by the patient or
compliance to therapy. A third study compared the initia-
tion of HMV between inpatient and outpatient titration but
did not use telemonitoring [16]. The improvement of blood
gasses was equivalent between the two groups which is
comparable to our study. However patients included in our
study had a mean PaCO2 of 6.6 kPa while in the study of
Chatwin patients had near normal daytime PaCO2.
Our data provides a good example in the field of
implementation of telemonitoring while not all studies
have been successful so far. We believe that the results of
this study contribute to the fact that the use of moderntechnologies in patients with a chronic disease can lower
the burden to the health care system.
Earlier studies showed an improvement in blood gasses
after the initiation of HMV [17,18]. We found a comparable
improvement in blood gasses in both groups indicating that
the initiation of HMV can be performed effectively at home
in a selective group of patients with chronic respiratory
failure due to a neuromuscular disease of thoracic cage
disorder. Nevertheless it is obvious that a thorough scan of
the home environment must be performed before starting
HMV.
This study also showed that it is possible to initiate HMV
at home in patients with an age varying from 19 to 80 years
of age. The youngest and the oldest started HMV at home
and we did not notice any age related problems. In some
cases the absence of a partner or family member resulted
in recruiting home care professionals to support the patient
during the first steps of HMV at home. In the home group
Figure 4 Time spent during initiation of home mechanical
ventilation and 6 months follow-up. Contact: direct contact
between the patient and the care giver of the department of
home mechanical ventilation from initiation to 6 months
follow-up. Travel time: driving time between hospital and pa-
tient during house calls. Total: is all time added up.
1394 A. Hazenberg et al.patients started HMV one week after being included and in
the hospital group this was 3 weeks. This delay in the
hospital group was due to limited number of beds in the
hospital.
As in our center the initiation of HMV is done in a hos-
pital based setting and therefore expensive, the present
study was performed to search for an alternative. The
medical ethics committee agreed to initiate HMV outside
the hospital directly instead of starting in an outpatient
clinic or on a ward without ICU admission first. This was
done to save time and to facilitate patients to stay at
home. Initiating HMV at home was not only effective and
safe, it was also cost-effective. This study showed a mean
reduction of V 3187 per patient when HMV started at home.
Mobile data communication costs were negligible and var-
iable and therefore not included in the total costs analysis.
Since we initiate HMV in the Netherlands in approximately
600 patients per year [19], full implementation nationwide
would save over V 1.8 million annually. Despite this enor-
mous cost reduction we should stress the point that the
inpatient initiation is very expensive being primarily due to
the ICU admission. When the initiation is done on a non-ICU
ward the benefit in costs would be lower compared to our
situation.
Despite these positive results this study has some
limitations.
Above all, there was a large group of patients with
chronic respiratory failure that did not participate in this
study for various reasons (Fig. 1). We excluded all patients
with COPD as providing HMV to this group is still not current
practice in our country. A recent meta-analysis showed that
HMV in stable patients with COPD did not improve gas-
exchange, lung function or QOL [20]. In this study only 2
patients with OHS were enrolled which is remarkable
considering the growth of patients with OHS that start HMV
[21]. The reason was that 27 patients with OHS had to start
with HMV in hospital immediately due to an acute respira-
tory failure.
Secondly, the effect of HMV with regard to quality of life
(QOL) in our total group compared to previous studiesseems to be less positive. Probably this is due to the large
number of ALS patients included in our study, which was
over the 35%. Although Bourke concluded that HMV in ALS
does improve QOL, this was based on the increased dura-
tion of time (compared to control group) that the QOL was
maintained above 75% of their baseline value [22]. As we
assessed absolute values of QOL it is difficult to compare
both studies. If we excluded the ALS group we did find a
significant improvement in several domains being compa-
rable with the previous studies.
Another limitation of this study was that the initiation of
HMV was done by just one NP in the home group. As we
cannot conclude, based on this single study, that it can be
duplicated in all other situations, we recommend an addi-
tional study were the implementation of this concept on a
broader scale i.e. other regions, settings and with more
people involved should be examined. Improvements in the
technical and digital opportunities, during the last couple
of years, will facilitate the development of future tele-
monitoring studies. Especially the use of polysomnography
and microchip cards with detailed ventilator information,
can be of great importance in future studies to better
evaluate the patient-ventilator interaction.
Conclusion
In summary we showed that initiation of HMV at home in a
selective group of patients with chronic respiratory failure
due to neuromuscular disease or thoracic cage disorder is
effective for gas exchange and quality of life and is not less
effective than initiation in the hospital. In addition we
found that it is safe and that more than V 3000 per patient
can be saved. From a patients’ perspective it is an ideal
treatment as they do not have to be admitted to the hos-
pital and their highly individualised care can be maintained
during the initiation of HMV.
Statement of interest
This study was financially supported by the Health Care
Insurance Board in the Netherlands, the University Medical
Center Groningen, Vivisol Area UK & Benelux and ResMed.Acknowlegdements
We are very grateful to all the patients, their family
members and the homecare professionals who kindly
agreed to participate in this study and to everyone who
worked on this project. We would also like to thank the
members of the Data Safety Monitoring Board; Prof. Dr. J.G.
Zijlstra, Prof. Dr. E.R. van den Heuvel (University Medical
Center Groningen) and Mw. Drs. A.F. Meinesz for their
contribution.Appendix A. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.rmed.2014.07.008.
Initiation of home mechanical ventilation at home 1395References




[2] van der Kooi TI, Mannien J, Wille JC, van Benthem BH. Prev-
alence of nosocomial infections in The Netherlands,
2007e2008: results of the first four national studies. J Hosp
Infect 2010;75:168e72.
[3] Inglis SC, Clark RA, McAlister FA, Stewart S, Cleland JG. Which
components of heart failure programmes are effective? A
systematic review and meta-analysis of the outcomes of
structured telephone support or telemonitoring as the primary
component of chronic heart failure management in 8323 pa-
tients: abridged cochrane review. Eur J Heart Fail 2011;13:
1028e40.
[4] de Almeida JP, Pinto AC, Pereira J, Pinto S, de Carvalho M.
Implementation of a wireless device for real-time telemedical
assistance of home-ventilated amyotrophic lateral sclerosis
patients: a feasibility study. Telemed J E Health 2010;16:
883e8.
[5] Vitacca M, Bianchi L, Guerra A, Fracchia C, Spanevello A,
Balbi B, et al. Tele-assistance in chronic respiratory failure
patients: a randomised clinical trial. Eur Respir J 2009;33:
411e8.
[6] Clinical indications for noninvasive positive pressure ventila-
tion in chronic respiratory failure due to restrictive lung dis-
ease, COPD, and nocturnal hypoventilationea consensus
conference report. Chest 1999;116:521e34.
[7] Robert D, Willig TN, Leger P, Paulus J. Long-term nasal
ventilation in neuromuscular disorders: report of a consensus
conference. Eur Respir J 1993;6:599e606.
[8] Windisch W, Freidel K, Schucher B, Baumann H, Wiebel M,
Matthys H, et al. The severe respiratory insufficiency (SRI)
questionnaire: a specific measure of health-related quality of
life in patients receiving home mechanical ventilation. J Clin
Epidemiol 2003;56:752e9.
[9] Carone M, Bertolotti G, Anchisi F, Zotti AM, Donner CF,
Jones PW. Analysis of factors that characterize health
impairment in patients with chronic respiratory failure.
Quality of life in chronic respiratory failure group. Eur Respir J
1999;13:1293e300.
[10] Zigmond AS, Snaith RP. The hospital anxiety and depression
scale. Acta Psychiatr Scand 1983;67:361e70.[11] Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M,
Sanderman R, et al. Translation, validation, and norming of
the Dutch language version of the SF-36 Health Survey in
community and chronic disease populations. J Clin Epidemiol
1998;51:1055e68.
[12] Hazenberg A, Zijlstra JG, Kerstjens HA, Wijkstra PJ. Validation
of a transcutaneous CO(2) monitor in adult patients with
chronic respiratory failure. Respiration 2011;81:242e6.
[13] Hakkaart-van Roijne L, Tan SS, Bouwmans CAM. Manual for
costs research. Methods and standard prices for economic
evaluations in health care; 2010.
[14] Pinto A, Almeida JP, Pinto S, Pereira J, Oliveira AG, de
Carvalho M. Home telemonitoring of non-invasive ventilation
decreases healthcare utilisation in a prospective controlled
trial of patients with amyotrophic lateral sclerosis. J Neurol
Neurosurg Psychiatry 2010;81:1238e42.
[15] Bertini S, Picariello M, Gorini M, Renda T, Augustynen A,
Villella G, et al. Telemonitoring in chronic ventilatory failure:
a new model of survellaince, a pilot study. Monaldi Arch Chest
Dis 2012;77:57e66.
[16] Chatwin M, Nickol AH, Morrell MJ, Polkey MI, Simonds AK.
Randomised trial of inpatient versus outpatient initiation of
home mechanical ventilation in patients with nocturnal
hypoventilation. Respir Med 2008;102:1528e35.
[17] Janssens JP, Derivaz S, Breitenstein E, De Muralt B, Fitting JW,
Chevrolet JC, et al. Changing patterns in long-term noninva-
sive ventilation: a 7-year prospective study in the Geneva
Lake area. Chest 2003;123:67e79.
[18] Windisch W. Impact of home mechanical ventilation on
health-related quality of life. Eur Respir J 2008;32:1328e36.
[19] Hazenberg A, Cobben NA, Kampelmacher MJ, Rischen J,
Wijkstra PJ. Home mechanical ventilation in the Netherlands.
Ned Tijdschr Geneeskd 2012;156:A3609.
[20] Struik FM, Lacasse Y, Goldstein RS, Kerstjens HA, Wijkstra PJ.
Nocturnal noninvasive positive pressure ventilation in stable
COPD: a systematic review and individual patient data meta-
analysis. Respir Med 2014;108:329e37.
[21] Gaytant MA, Westermann EJ, Zelissen PM, Kampelmacher MJ.
Obesity hypoventilation syndromeeserious but reversible
providingweight is lost. Ned Tijdschr Geneeskd 2011;155:A2914.
[22] Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ,
Gibson GJ. Effects of non-invasive ventilation on survival and
quality of life in patients with amyotrophic lateral sclerosis: a
randomised controlled trial. Lancet Neurol 2006;5:140e7.
